The FDA has approved trastuzumab deruxtecan (DS-8201) for use in patients with locally advanced or metastatic HER2-positive G/GEJ adenocarcinoma who have been treated with trastuzumab based on the results of the DESTINY-Gastric01 trial [118]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.